Top

Published in:

01-10-2013 | Research Article

Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma

Authors: Guan-Xian Liu, Xin Zhang, Su Li, Richard D. Koiiche, Jerry H. Sindsceii, Haihan Song

Published in: Tumor Biology | Issue 5/2013

Abstract

Monocyte chemoattractant protein-1 (MCP-1) and its receptor CC chemokine receptor 2 (CCR2) play a major role in inflammation and proliferation of cancers. We investigated a possible association between polymorphisms in MCP-1 and CCR2 genes (MCP-1 -2518A/G and CCR2 190G/A or V64I) and the risk as well as prognosis of renal cell carcinoma (RCC). Genotypes were determined by polymerase chain reaction–restriction fragment length polymorphism in 416 RCC cases and 458 age-matched healthy controls. Frequency of MCP-1 2518GG genotype for cases and controls was 0.384 and 0.286, respectively; individuals carrying the GG genotype had a 1.89-fold increased risk of RCC than those with AA genotype (95 % confidence interval [CI] 1.24–2.81, p = 0.002; data were adjusted for age and sex). Frequency of CCR2 190AA (64I/64I) genotype for cases and controls was 0.175 and 0.076, respectively; subjects having AA genotype had a 2.68-fold increased risk of RCC compared to those with the wild-type GG genotype (95 %CI 1.71–4.17, p = 4.3 × 10⁻⁶; data were adjusted for age and sex). When analyzing the survival rate of RCC, patients with MCP-1 -2518GG genotype revealed significantly shorter survival time compared to cases with MCP-1 -2518AA and AG genotypes (p = 0.003). Similarly, RCC cases carrying CCR2 190AA genotype showed significantly shorter survival rate than patients with GG or GA genotypes (p < 0.001). These data suggested that MCP-1 -2518A/G and CCR2 190G/A polymorphisms are new risk factors for RCC and could be used as prognostic markers for this malignancy.

Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.CrossRefPubMed

Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27:177–86.PubMed

Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med. 1989;169:1449–59.CrossRefPubMed

Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29:313–26.PubMedCentralCrossRefPubMed

Barna BP, Pettay J, Barnett GH, Zhou P, Iwasaki K, Estes ML. Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor (TNF) or antibody to the 55-kDa TNF receptor. J Neuroimmunol. 1994;50:101–7.CrossRefPubMed

Brown Z, Strieter RM, Neild GH, Thompson RC, Kunkel SL, Westwick J. IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells. Kidney Int. 1992;42:95–101.CrossRefPubMed

Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134–8.PubMedCentralCrossRefPubMed

Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010;21:41–8.PubMedCentralCrossRefPubMed

Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010;102:522–8.PubMedCentralCrossRefPubMed

10.

Craig MJ, Loberg RD. CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev. 2006;25:611–9.CrossRefPubMed

11.

Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 2006;66:1311–8.CrossRefPubMed

12.

Mazzucchelli L, Loetscher P, Kappeler A, Uguccioni M, Baggiolini M, Laissue JA, et al. Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am J Pathol. 1996;149:501–9.PubMedCentralPubMed

13.

Chetcuti A, Margan S, Mann S, Russell P, Handelsman D, Rogers J, et al. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate. 2001;47:132–40.CrossRefPubMed

14.

Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 2006;8:578–86.PubMedCentralCrossRefPubMed

15.

Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 2009;69:1685–92.PubMedCentralCrossRefPubMed

16.

Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007;9:556–62.PubMedCentralCrossRefPubMed

17.

Hu H, Sun L, Guo C, Liu Q, Zhou Z, Peng L, et al. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res. 2009;15:5485–93.CrossRefPubMed

18.

Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999;259:344–8.CrossRefPubMed

19.

Tse KP, Tsang NM, Chen KD, Li HP, Liang Y, Hsueh C, et al. MCP-1 promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res. 2007;13:6320–6.CrossRefPubMed

20.

Flores-Villanueva PO, Ruiz-Morales JA, Song CH, Flores LM, Jo EK, Montano M, et al. A functional promoter polymorphism monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis. J Exp Med. 2005;202:1649–58.PubMedCentralCrossRefPubMed

21.

Cho ML, Kim JY, Ko HJ, Kim YH, Kim WU, Cho CS, et al. The MCP-1 promoter -2518 polymorphism in Behcet’s disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients. Autoimmunity. 2004;37:77–80.CrossRefPubMed

22.

Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, et al. Effects of CCR5-Delta, 32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135:782–95.CrossRefPubMed

23.

Miyagishi R, Niino M, Fukazawa T, Yabe I, Kikuchi S, Tashiro K. CC chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol. 2001;145:135–8.CrossRef

24.

Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet. 2004;41:59.CrossRef

25.

Coelho A, Matos A, Catarino R, Pinto D, Pereira D, Lopes C, et al. Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol. 2005;96:760–4.CrossRefPubMed

26.

Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2 V64I polymorphism affects stability of CCR2A isoform. AIDS. 2004;18:729–38.CrossRefPubMed

27.

Dawson SJ, Morris PJ, Latchman DS. A single amino acid change converts an inhibitory transcription factor into an activator. J Biol Chem. 1996;271:11631–3.CrossRefPubMed

Title: Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma
Authors: Guan-Xian Liu
Xin Zhang
Su Li
Richard D. Koiiche
Jerry H. Sindsceii
Haihan Song
Publication date: 01-10-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0827-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

The polymorphisms in the MGMT gene and the risk of cancer: a meta-analysis

Prognostic significance of VEGF immunohistochemical expression in oral cancer: a meta-analysis of the literature

Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells

Cytogenetic characterization of an N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse papillary urothelial carcinoma

RETRACTED ARTICLE: Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population

RETRACTED ARTICLE: Silencing of the Smad nuclear interacting protein 1 (SNIP1) by siRNA inhibits proliferation and induces apoptosis in pituitary adenoma cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer